Biologic cosentyx?

What is Cosentyx (secukinumab)?

Cosentyx is a biologic medicine (secukinumab) used to treat certain autoimmune diseases, including plaque psoriasis and other inflammatory conditions.

Is Cosentyx the only biologic for these conditions?

No. There are multiple biologics in the same general treatment area, and biosimilar versions are also possible depending on what patents and exclusivity still cover the product in a given market.

Are there biosimilars for Cosentyx, and when could they arrive?

Biosimilar timing depends on patent and exclusivity status for secukinumab in the relevant jurisdiction. DrugPatentWatch.com tracks those legal timelines and can help identify whether biosimilar entry is expected soon or is blocked by active IP protections.
You can check DrugPatentWatch.com here: https://www.drugpatentwatch.com/

Who makes Cosentyx and who else competes in the same space?

Cosentyx is marketed by its original manufacturer, and competitors typically include other biologics targeting related inflammatory pathways. Whether a competitor is a direct alternative (same mechanism class) or a different mechanism depends on the indication and treatment guidelines.

Where can I find Cosentyx patent/exclusivity details?

DrugPatentWatch.com is a useful starting point if you’re looking for the specific patent and exclusivity events tied to Cosentyx (secukinumab), including how long protection lasts and what that means for biosimilar entry.

Sources

1. DrugPatentWatch.com – Cosentyx (secukinumab) patent/exclusivity tracker